AB133563

重组Anti-Urokinase抗体[EPR6273]

Anti-Urokinase antibody [EPR6273]

RabMAb
Recombinant
了解详情

Be the first to review this product! Submit a review

(10 Publications)

Rabbit Recombinant Monoclonal Urokinase antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 10 publications.

查看别名

Urokinase-type plasminogen activator, U-plasminogen activator, uPA, PLAU

5 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Urokinase antibody [EPR6273] (AB133563)

IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Urokinase antibody [EPR6273] (AB133563)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling Urokinase with purified ab133563 at 1/150. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Negative control using PBS instead of primary antibody. Counterstained with Hematoxylin.

Lab

Western blot - Anti-Urokinase antibody [EPR6273] (AB133563)

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Western blot - Anti-Urokinase antibody [EPR6273] (ab133563) at 1/100 dilution

Lane 1:

LnCap cell lysate at 10 µg

Lane 2:

PC-3 cell lysate at 10 µg

Secondary

All lanes:

Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

Predicted band size: 49 kDa

Observed band size: 49 kDa

false

Lab

Western blot - Anti-Urokinase antibody [EPR6273] (AB133563)

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Western blot - Anti-Urokinase antibody [EPR6273] (ab133563) at 1/1300 dilution

Lane 1:

LnCaP cell lysate at 10 µg

Lane 2:

PC-3 cell lysate at 10 µg

Secondary

All lanes:

Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

Predicted band size: 49 kDa

Observed band size: 49 kDa

false

Unknown

Western blot - Anti-Urokinase antibody [EPR6273] (AB133563)

All lanes:

Western blot - Anti-Urokinase antibody [EPR6273] (ab133563) at 1/1000 dilution

Lane 1:

PC-3 cell lysate at 10 µg

Lane 2:

LnCaP cell lysate at 10 µg

Lane 3:

MCF7 cell lysate at 10 µg

Secondary

All lanes:

HRP-conjugated goat anti-rabbit IgG at 1/2000 dilution

Predicted band size: 49 kDa

true

OI-RD Scanning - Anti-Urokinase antibody [EPR6273] (AB133563)

OI-RD Scanning

Unknown

OI-RD Scanning - Anti-Urokinase antibody [EPR6273] (AB133563)

We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

不同偶联物与剂型 (1)

Carrier free

Anti-Urokinase antibody [EPR6273] - BSA and Azide free

关键信息

宿主种属

Rabbit

克隆

Monoclonal

克隆号

EPR6273

亚型

IgG

不含载体蛋白

反应种属

Human

应用

IHC-P, WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "1/540", "FlowCyt-species-notes": "For unpurified use at 1/50.<a href='/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "For unpurified use at 1/100.", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/150", "IHCP-species-notes": "" }, "Mouse": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Rat": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

style

left-column

产品详情

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

性能和储存信息

形式

Liquid

纯化工艺

Affinity purification Protein A

存储溶液

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

运输条件

Blue Ice

分装信息

Upon delivery aliquot

储存信息

Stable for 12 months at -20°C

style

left-column

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

Urokinase also known as urokinase-type plasminogen activator (uPA) is a serine protease with a molecular mass of approximately 54 kDa. It is expressed in various tissues including the kidneys liver and blood vessels. Urokinase initially forms as pro-urokinase an inactive precursor that can convert into the active enzyme. Researchers often use assays like the direct assay to measure urokinase activity due to its role in breaking down fibrin and modulating cell adhesion and migration.

Biological function summary

Something particularly interesting about urokinase is its role in converting plasminogen to plasmin a critical enzyme in the process of fibrinolysis. Moreover it is part of a larger enzymatic complex involving the urokinase receptor (uPAR) which localizes plasminogen activation to cell surfaces. This complex mediates extracellular matrix degradation aiding in important cellular processes like tissue remodeling and wound healing.

Pathways

Urokinase plays a critical role in the fibrinolytic pathway which involves the breakdown of blood clots. It also interacts with the extracellular matrix pathway by activating plasminogen which can degrade matrix components. In these pathways urokinase closely interacts with proteins such as plasmin and its inhibitor plasminogen activator inhibitor-1 (PAI-1) which regulate the activity and localization of proteolytic events.

Urokinase is strongly linked to conditions such as deep vein thrombosis and cancer metastasis. Its overexpression or dysregulation often leads to excessive tissue degradation influencing metastasis progression. Urokinase is connected to the urokinase receptor (uPAR) in cancer facilitating cancer cell invasion and migration. Understanding its behavior in these contexts is critical for developing therapeutic strategies and targeting treatments against these diseases.

style

left-column

style

left-column

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

靶点信息

Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.

See full target information Urokinase-type plasminogen activator

style

left-column

文献 (10)

Recent publications for all applications. Explore the full list and refine your search

Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 43:45-60 PubMed37824369

2024

Comprehensive Investigation of m6A Regulators for Prognosis in Head and Neck Squamous Cell Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Jingning Cheng,Yong Lyu,Ziyan Cheng

JCI insight 9: PubMed38502232

2024

Dysregulated fibrinolysis and plasmin activation promote the pathogenesis of osteoarthritis.

Applications

Unspecified application

Species

Unspecified reactive species

Qian Wang,Guoqiang Shao,Xiaoyi Zhao,Heidi H Wong,Kate Chin,Mackenzie Zhao,Audrey Bai,Michelle S Bloom,Zelda Z Love,Constance R Chu,Zhen Cheng,William H Robinson

Frontiers in cell and developmental biology 10:770550 PubMed35300428

2022

An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Lung Squamous Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Wen-Yu Zhai,Fang-Fang Duan,Si Chen,Jun-Ye Wang,Ze-Rui Zhao,Yi-Zhi Wang,Bing-Yu Rao,Yao-Bin Lin,Hao Long

Cancer cell international 21:564 PubMed34702271

2021

Hypomethylation and downregulation of miR-23b-3p are associated with upregulated PLAU: a diagnostic and prognostic biomarker in head and neck squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Zirong Huo,Xiaoguang Li,Jieyu Zhou,Yuqin Fan,Zhentao Wang,Zhihua Zhang

Urologic oncology 38:685.e17-685.e25 PubMed32381392

2020

The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy.

Applications

Unspecified application

Species

Unspecified reactive species

Mohammad Abufaraj,Shoji Kimura,Andrea Haitel,Takihero Iwata,Ula Isleem,David D'Andrea,Francesco Soria,Keiichiro Mori,Michael Rink,Karim Bensalah,Morgan Rouprêt,Vitaly Margulis,Alberto Briganti,Pierre I Karakiewicz,Shahrokh F Shariat

Medicine 98:e17031 PubMed31689742

2019

Alterations in complement and coagulation pathways of human placentae subjected to in vitro fertilization and embryo transfer in the first trimester.

Applications

Unspecified application

Species

Unspecified reactive species

Liang Zhao,Lifang Sun,Xiuli Zheng,Jingfang Liu,Rong Zheng,Rui Yang,Ying Wang

Journal of cellular and molecular medicine 23:5176-5192 PubMed31251468

2019

The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model.

Applications

Unspecified application

Species

Unspecified reactive species

Maurizio Cammalleri,Massimo Dal Monte,Filippo Locri,Valeria Pecci,Mario De Rosa,Vincenzo Pavone,Paola Bagnoli

International journal of clinical oncology 24:1030-1041 PubMed30937621

2019

Identification of SERPINE1, PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis.

Applications

Unspecified application

Species

Unspecified reactive species

Ke Yang,Shizhou Zhang,Dongsheng Zhang,Qian Tao,Tianqi Zhang,Guijun Liu,Xingguang Liu,Tengda Zhao

Reproductive biology and endocrinology : RB&E 17:33 PubMed30878040

2019

Expression of the plasminogen system in the physiological mouse ovary and in the pathological polycystic ovary syndrome (PCOS) state.

Applications

Unspecified application

Species

Unspecified reactive species

Genia F Burchall,Dodie S Pouniotis,Helena J Teede,Sanjeeva Ranasinha,Kirsty A Walters,Terrence J Piva

Molecular medicine reports 13:4593-8 PubMed27082639

2016

Thrombosis recanalization by paeoniflorin through the upregulation of urokinase‑type plasminogen activator via the MAPK signaling pathway.

Applications

Species

Human

Songshan Ye,Bingyu Mao,Lei Yang,Weiyun Fu,Junran Hou

View all publications

style

left-column

style

left-column

style

right-column

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂，为您科研的每一步提供支持。若我们的产品未能达到预期性能，我们向您提供 Abcam Product Promise 保障。

详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

重组Anti-Urokinase抗体[EPR6273]